SuperworthZoetis profit margin ZTS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.
- Net margin, 12 months
- 27.5%
- Operating margin, 12 months
- 36.4%
- Net margin on a year earlier
- −0.1 pts
- Peer median
- 17.7%
Over the twelve months to Jun 30, 2026, Zoetis kept 27.5% of its revenue as net profit, with an operating margin of 36.4% and a gross margin of 71.5%.
Five years earlier its net margin was 25.8%.
The median for 10 healthcare stocks of a similar size is 17.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 28.0% | 37.2% | 71.7% |
| FY2024 | 26.9% | 36.1% | 70.6% |
| FY2023 | 27.4% | 35.3% | 70.0% |
| FY2022 | 26.2% | 36.1% | 69.6% |
| FY2021 | 26.2% | 35.5% | 70.4% |
| FY2020 | 24.5% | 33.6% | 69.2% |
| FY2019 | 24.0% | 31.4% | 68.2% |
| FY2018 | 24.5% | 29.0% | 67.2% |
| FY2017 | 16.3% | 28.7% | 66.6% |
| FY2016 | 16.8% | 25.1% | 65.9% |
| FY2015 | 7.1% | 11.4% | 63.5% |
| FY2014 | 12.2% | 17.1% | 64.1% |
| FY2013 | 11.1% | 15.1% | 63.4% |
| FY2012 | 10.1% | 16.4% | 64.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 27.5% | −0.1 pts | 36.4% | |
| Q1 FY26 | 27.8% | +1.0 pts | 36.8% | |
| Q4 FY25 | 28.0% | +1.2 pts | 37.2% | |
| Q3 FY25 | 28.0% | +1.5 pts | 37.0% | |
| Q2 FY25 | 27.6% | +1.3 pts | 36.9% | |
| Q1 FY25 | 26.9% | −0.5 pts | 36.2% | |
| Q4 FY24 | 26.9% | −0.6 pts | 36.1% | |
| Q3 FY24 | 26.6% | −0.7 pts | 35.8% | |
| Q2 FY24 | 26.3% | −0.6 pts | 35.3% | |
| Q1 FY24 | 27.4% | +1.8 pts | 35.6% | |
| Q4 FY23 | 27.4% | +1.3 pts | 35.3% | |
| Q3 FY23 | 27.2% | +1.4 pts | 35.9% |
Against its peers
Companies in Healthcare nearest Zoetis' size, closest first, today.
| Company | Profit margin |
|---|---|
| ZTSZoetis | 27.5% |
| MTDMettler-Toledo International | 21.9% |
| CNCCentene | −2.5% |
| GEHCGE HealthCare Technologies | 9.3% |
| RMDResMed | 26.9% |
| RPRXRoyalty Pharma | 32.1% |
| BIIBBiogen | 8.3% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| DXCMDexCom | 20.1% |
| WSTWest Pharmaceutical Services | 17.0% |
| ILMNIllumina | 18.4% |
| Peer median | 17.7% |
Where Zoetis ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Zoetis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.